Compare Heron Therapeutics Inc (HRTX) vs PubMatic Inc (PUBM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs PubMatic Inc — how do they compare? Heron Therapeutics Inc trades at $0.4 (market cap $68.01M), while PubMatic Inc trades at $18.67 (market cap $850.88M). The key difference: PubMatic Inc is far larger — about 12.5× Heron Therapeutics Inc's market cap, and PubMatic Inc is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 35 Days and PubMatic Inc for 40 Days on average.
| HRTX | PUBM | |
|---|---|---|
Market Cap | $68.01M | $850.88M |
Volume | 1,891,941 | 997,698 |
Sector | Health | Technology |
52-Week High | $1.49 | $19.18 |
52-Week Low | $0.27 | $6.28 |
Typical Hold Time | 35 Days | 40 Days |
Enterprise Value | $174.75M | $754.01M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.3967, up 1.72% today, with a bullish technical signal from moving averages but mixed earnings. The company reported a net loss of $20.20 million in 2025, with revenue of $154.90 million, and has a high gross margin of 70.07% but negative profitability metrics. Recent Q2 2026 results missed EPS estimates, though Q4 2025 beat expectations. Analyst consensus is strongly bullish with 17 buy ratings.
The outlook is cautious due to persistent losses and cash burn, but strong analyst support and a low P/S ratio of 0.44 may appeal to value investors. Key risks include ongoing unprofitability and competitive pressures in the biotech sector. Investors should weigh the high institutional optimism against fundamental challenges.
PubMatic (PUBM) trades at $18.64, up 0.38% on the day, with a bullish technical signal driven by moving averages. The stock has beaten earnings estimates for the last three quarters, though it remains unprofitable with a negative net income margin. Recent news highlights strong Q2 2026 results, AI product adoption, and executive appointments, fueling positive sentiment.
The outlook is cautiously optimistic given analyst consensus and technical momentum, but risks include persistent profitability challenges and competitive pressures. Upside is supported by a $19.89 average price target, though investors should weigh high valuation multiples against earnings growth potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About PubMatic Inc
PubMatic Inc is engaged in the digital advertising business. The company provides a specialized cloud infrastructure platform that enables real-time programmatic advertising transactions. The platform helps independent app developers and publishers to control and maximize their digital advertising businesses.
Read more on PUBM →
